Continuous Glucose Monitoring: A Case Study for Commercializing Products In The Era of Patient-Driven Health Care
Continuous glucose monitoring for patients with diabetes presents an example of how an individual product has far less value than the integrated solution the technology enables. While continuous glucose monitoring offers significant value to a broad range of patients, the technology has still not fulfilled its market potential. Factors hindering more widespread adoption include inaccuracy, difficulty in using the systems, and low levels of patient adherence. But the greatest obstacle in CGM is the disconnect between CGM and treatment planning; CGM produces mounds of data that patients and even physicians don't know how to use. According to Health Care Advances, if this powerful dataset is optimized, shared, and applied, it could shift CGM from a niche product for a small number of type 1 diabetes patients into a standard of care for many metabolic diseases.
Marie Schiller, Sheela Hegde, and Brittany Birrell Carroll
Continuous glucose monitoring has yet to achieve its full potential. Over the five years that continuous glucose monitoring (CGM) has...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
